UY37636A - Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1 - Google Patents

Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1

Info

Publication number
UY37636A
UY37636A UY0001037636A UY37636A UY37636A UY 37636 A UY37636 A UY 37636A UY 0001037636 A UY0001037636 A UY 0001037636A UY 37636 A UY37636 A UY 37636A UY 37636 A UY37636 A UY 37636A
Authority
UY
Uruguay
Prior art keywords
cngb1
pigmental
retinitis
linked
treatment
Prior art date
Application number
UY0001037636A
Other languages
English (en)
Spanish (es)
Inventor
Stylianos Michalakis
Martin Biel
Original Assignee
Univ Muenchen Ludwig Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Ludwig Maximilians filed Critical Univ Muenchen Ludwig Maximilians
Publication of UY37636A publication Critical patent/UY37636A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001037636A 2017-03-21 2018-03-21 Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1 UY37636A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762474409P 2017-03-21 2017-03-21

Publications (1)

Publication Number Publication Date
UY37636A true UY37636A (es) 2018-10-31

Family

ID=62044771

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037636A UY37636A (es) 2017-03-21 2018-03-21 Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1

Country Status (10)

Country Link
US (2) US12246072B2 (enExample)
EP (1) EP3600446A1 (enExample)
JP (1) JP7257377B2 (enExample)
CN (1) CN111050805A (enExample)
AR (1) AR111188A1 (enExample)
AU (1) AU2018238422B2 (enExample)
CA (1) CA3056211A1 (enExample)
TW (1) TW201902911A (enExample)
UY (1) UY37636A (enExample)
WO (1) WO2018172961A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220175969A1 (en) * 2019-03-04 2022-06-09 University Of Florida Research Foundation, Incorporated Enhanced human opsin promoter for rod specific expression
WO2020182722A1 (en) * 2019-03-08 2020-09-17 Universite Paris-Saclay Improved therapeutic method for rare ocular diseases by gene replacement
CN110241202A (zh) * 2019-06-25 2019-09-17 复旦大学附属眼耳鼻喉科医院 视网膜色素变性突变位点及其应用
JP2022549138A (ja) 2019-09-18 2022-11-24 インターガラクティック セラピューティクス インコーポレイテッド 合成dnaベクターおよびその使用法
WO2021146625A1 (en) * 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
US20230174598A1 (en) * 2020-03-18 2023-06-08 University Of Florida Research Foundation, Incorporated Modified arrestin-1 to enhance photoreceptor survival in retinal disease
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
JP2023548746A (ja) * 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
CN113201556B (zh) * 2021-05-14 2022-11-22 浙江大学 pSOY19-ZM2载体、其制备方法及应用
WO2023280388A1 (en) * 2021-07-06 2023-01-12 Institute Of Molecular And Clinical Ophthalmology Basel Promoter for specific expression of genes in rod photoreceptors
CN115820653A (zh) * 2021-09-17 2023-03-21 深圳华大生命科学研究院 基因突变体及其应用
CN119432856B (zh) * 2024-12-30 2025-08-12 云舟生物科技(广州)股份有限公司 核酸分子、病毒颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2140004B1 (en) * 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
US11246947B2 (en) 2013-08-05 2022-02-15 Academisch Ziekenhuis Leiden H.O.D. N. Leids Universitair Medisch Centrum Recombinant AAV-crumbs homologue composition and methods for treating LCA-8 and progressive RP
ES2760263T3 (es) * 2014-03-21 2020-05-13 Genzyme Corp Tratamiento génico de la retinitis pigmentaria
EP3210632B1 (en) * 2016-02-23 2022-09-28 EyeServ GmbH Gene therapy for the treatment of a retinal degeneration disease

Also Published As

Publication number Publication date
US20250262328A1 (en) 2025-08-21
JP2020511167A (ja) 2020-04-16
US12246072B2 (en) 2025-03-11
JP7257377B2 (ja) 2023-04-13
AU2018238422B2 (en) 2025-04-03
EP3600446A1 (en) 2020-02-05
TW201902911A (zh) 2019-01-16
AU2018238422A1 (en) 2019-10-03
CA3056211A1 (en) 2018-09-27
WO2018172961A1 (en) 2018-09-27
AR111188A1 (es) 2019-06-12
US20200030458A1 (en) 2020-01-30
CN111050805A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
UY37636A (es) Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1
IL272105A (en) Local administration of pharmaceutical agents containing cell-penetrating peptides for use in the treatment of age-related macular degeneration and other eye diseases
CL2019003091A1 (es) Terapia de combinación.
ECSP16083000A (es) Terapia genica para la retinitis pigmentaria
MX2019007873A (es) Terapia génica para tratar la enfermedad de wilson.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
PE20210473A1 (es) Derivados de gip y usos de estos
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
BR112016019432A2 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
PH12021550872A1 (en) Therapeutic compounds
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CO2021016487A2 (es) Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
MX2019008621A (es) Peptidos terapeuticos y neuroprotectores.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
AR119609A1 (es) Partículas virales para uso en el tratamiento de sinucleinopatías tales como enfermedades de parkinson mediante terapia génica
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
MX2022004212A (es) Moduladores de atf6 y usos de los mismos.
DOP2017000116A (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2022004219A (es) Moduladores de atf6 y usos de los mismos.
CO2022008421A2 (es) Promotores específicos para neuronas bipolares activadas para el suministro ocular de genes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231026